Please try another search
For the nine months ended 30 September 2019, Advanz Pharma Corp Ltd revenues decreased 8% to $386.4M. Net loss totaled $171.4M vs. income of $1.55B. Revenues reflect ADVANZ PHARMA International segment decrease of 9% to $284.7M, ADVANZ PHARMA North America segment decrease of 6% to $101.6M, United Kingdom & Jersey segment decrease of 36% to $122.3M, All other countries. segment decrease of 27% to $78.7M, Barbados segment decrease of 29% to $71.5M.
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Revenue | 119.64 | 131.08 | 135.64 | 117.57 |
Gross Profit | 81 | 85.47 | 91.11 | 78.15 |
Operating Income | -111.81 | -8.1 | 5.49 | -61.85 |
Net Income | -119.17 | -44.26 | -7.99 | -84.93 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Assets | 1593.76 | 1759.71 | 1875.03 | 1830.94 |
Total Liabilities | 1604.8 | 1616.29 | 1669.36 | 1634.28 |
Total Equity | -11.04 | 143.43 | 205.67 | 196.66 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | 150.86 | 97.42 | 45.95 | 141.62 |
Cash From Investing Activities | -31.33 | -31.25 | -0.54 | -1.97 |
Cash From Financing Activities | -90.21 | -64.75 | -25.22 | -224.68 |
Net Change in Cash | 18.91 | -0.13 | 24.15 | -102.59 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review